Drugs / KBP-042
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03230786 | Aug 2017 → Jul 2018 | type 2 diabetes mellitus | KeyBioscience AG | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-042 | “Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin” NCT03230786 ↗ |